{
    "clinical_study": {
        "@rank": "4779", 
        "arm_group": [
            {
                "arm_group_label": "Negative Control", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Positive Control", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Active", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effect of stearidonic acid when used as a food\n      ingredient on eicosapentaenoic enrichment of red blood cell membranes and Omega-3 Index in\n      men and women."
        }, 
        "brief_title": "Effects of Stearidonic Acid-Containing Foods on Eicosapentaenoic Acid Levels in Red Blood Cells and Omega-3 Index", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Sudden Cardiac Death", 
            "Sudden Cardiac Arrest", 
            "Cardiovascular Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Heart Arrest", 
                "Death, Sudden, Cardiac", 
                "Death"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, 21 to 65 years of age.\n\n          2. BMI) \u226518.00 and <40.00 kg/m2.\n\n          3. No health conditions that would prevent him/her from fulfilling the study\n             requirements as judged by the Investigator on the basis of medical history and\n             routine laboratory test results.\n\n          4. Willing to avoid alcohol consumption for 24 h prior to every clinic visit.\n\n          5. No plans to change smoking habits during the study period.\n\n          6. Willing to maintain a stable body weight, activity level and dietary pattern except\n             for use of the study products, as directed.\n\n          7. Understands the study procedures and signs forms providing informed consent to\n             participate in the study and authorization for release of relevant protected health\n             information to the study Investigator.\n\n        Exclusion Criteria:\n\n          1. Subject has coronary heart disease or a coronary heart disease risk equivalent\n             including any of the following:\n\n               -  Diabetes mellitus\n\n               -  Clinical signs of atherosclerosis including peripheral arterial disease,\n                  abdominal aortic aneurysm, carotid artery disease\n\n               -  Presence of multiple risk factors that give a person a greater than 20% chance\n                  for developing coronary artery disease within 10 years.\n\n          2. Abnormal laboratory test results of clinical significance\n\n          3. TG \u2265400 mg/dL at visit 1, week -2.\n\n          4. Smokes more than one pack of cigarettes (20 cigarettes) per day.\n\n          5. History or presence of clinically important renal, hepatic, pulmonary, biliary,\n             gastrointestinal, neurologic or endocrine disorders that in the judgment of the\n             Investigator, would interfere with the subject's ability to provide informed consent,\n             comply with the study protocol Stable, treated hypothyroidism is allowed.\n\n          6. Uncontrolled hypertension\n\n          7. Unstable use within four weeks of visit 1 (week -2) of antihypertensive medications\n             or thyroid hormone replacement.\n\n          8. Use of any lipid-altering drugs, including statins, bile acid sequestrants,\n             cholesterol absorption inhibitors, fibrates, or prescription formulations of niacin\n             within four weeks of visit 1 (week -2) and throughout the study. If a subject needs\n             to wash off of a drug, he/she will be consented and then asked to return after the\n             four week washout.\n\n          9. Use of EPA/DHA from a drug or supplement within four months of visit 1\n\n         10. Frequent use (more than twice per month) of any non-study-related EPA/DHA containing\n             enriched foods (such as DHA-enriched eggs) within four months of visit 1, week -2 and\n             avoidance of these enriched foods throughout the study period\n\n         11. Use of seeds and oils containing a significant amount of ALA\n\n         12. Consumption of fatty fish (salmon, herring, mackerel, albacore tuna, or sardines)\n             more than twice per month\n\n         13. Use of any dietary supplement known to alter lipid metabolism\n\n         14. Use of any weight-loss medication\n\n         15. Use of any weight loss supplement or program within four weeks of visit 1\n\n         16. Known allergy or sensitivity to study products or any ingredients of the study\n             products.\n\n         17. Subject is unwilling to consume the study products (bars, beverages and capsules)\n             based on results from the taste testing of the study products at visit 1, week -2.\n\n         18. Subject has a history or presence of cancer in the prior two years, except for\n             non-melanoma skin cancer\n\n         19. Females who are pregnant, planning to be pregnant during the study period, lactating,\n             or women of childbearing potential who are unwilling to commit to the use of a\n             medically approved form of contraception throughout the study period. The method of\n             contraception must be recorded in the source documentation.\n\n         20. Current or recent history of (within 12 months of visit 1, week -2) or strong\n             potential for alcohol or substance abuse. Alcohol abuse will be defined as >14 drinks\n             per week (1 drink = 12 oz beer, 5 oz wine, or 1 \u00bd oz distilled spirits).\n\n         21. Exposure to any non-registered drug product within 30 days prior to the screening\n             visit (visit 1, week -2)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749202", 
            "org_study_id": "PRV-10001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Negative Control", 
                    "Active"
                ], 
                "description": "3 x 500 mg softgel capsules/day", 
                "intervention_name": "Sunflower Oil Softgels", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Positive Control", 
                "description": "3 x 500 mg softgel capsules/day", 
                "intervention_name": "EPA softgels", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Negative Control", 
                    "Positive Control"
                ], 
                "description": "3 servings/day", 
                "intervention_name": "Sunflower Oil Food", 
                "intervention_type": "Other", 
                "other_name": "Food"
            }, 
            {
                "arm_group_label": "Active", 
                "description": "3 servings/day", 
                "intervention_name": "SDA soybean Oil Food", 
                "intervention_type": "Other", 
                "other_name": "Food"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Omega 3 fatty acids", 
            "Omega 3 Index", 
            "Stearidonic acid (SDA)", 
            "Red Blood Cells", 
            "Lipids"
        ], 
        "lastchanged_date": "December 11, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Glen Ellyn", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60137"
                }, 
                "name": "Provident Clinical Research &Consulting"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_official": {
            "affiliation": "Solae, LLC", 
            "last_name": "Ratna Mukherjea, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "End of treatment EPA level in RBC membranes, expressed as a percent of total RBC membrane fatty acids", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749202"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Omega-3 Index", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "SDA percent of total RBC membrane fatty acids", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Triglycerides", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Fasting insulin", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "HOMA (IR) and HOMA (%B)", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Solae, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Provident Clinical Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Solae, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}